Accolate (zafirlukast) is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma. Available as a tablet, it blocks the effects of substances which cause constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.

Accolate was the first LTRA to be marketed in the USA and is now approved in over 60 countries, including the UK, Japan, Italy, Spain, Canada, Brazil and China.

Accolate is approved in the USA for adults and children aged 5 years and above.